Novartis gets U.S. approval to buy Fougera

Mon Jul 16, 2012 10:32pm IST

Stocks

   

* Novartis must give up rights to three medicinal creams

* Fougera will be folded into Sandoz generics unit

WASHINGTON, July 16 (Reuters) - Swiss drugmaker Novartis has won U.S. antitrust approval to close its purchase of generic dermatology products maker Fougera.

The Federal Trade Commission said on Monday that as a condition of approval, Novartis agreed to give up the rights to market three topical skin care medicines made by Tolmar Inc and to cancel a deal for a fourth.

Novartis said in May that it would buy Fougera for $1.53 billion from a consortium of private equity funds led by Nordic Capital, DLJ Merchant Banking and Avista Capital Partners.

The three generic creams that Novartis must give up marketing rights to are a topical solution to treat psoriasis, a local anesthetic, and a cream to treat rosacea, which causes chronically red skin, the FTC said.

In addition to generic dermatology products, Fougera also has a branded specialty pharmaceuticals business. It had 2011 sales of $429 million.

Fougera, based in Melville, New York, will be folded into Novartis' Sandoz generics unit.

A spokeswoman for Novartis was not immediately available to comment on Monday.

Economic Survey

Reuters Showcase

Asian Shares

Asian Shares

Oil's drop chills Asian stocks, inflation data boosts dollar  Full Article 

Legal Complaints

Legal Complaints

Government's payday from telecoms auction could be delayed  Full Article 

Rail Budget

Rail Budget

India aims to invest $137 billion in railways in next 5 years  Full Article | Full Coverage 

Gold Market

Gold Market

Gold holds up on Chinese demand, set to snap 4-week losing run  Full Article 

Breakingviews

Breakingviews

StanChart board clearout is only the first step  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage